12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MM-121: Phase II started

Merrimack began an international Phase II trial of MM-121 in combination with Tarceva erlotinib in 229 metastatic NSCLC patients. The trial will compare the combination vs. Tarceva alone in 2 groups of patients who have not received prior EGFR therapy: those whose...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >